Meet EXIT071, part of the first batch of Proof-of-Concept projects that joined the Biotech Booster program after the round of applications in 2024!
EXIT071 is a Dutch deep-tech company, spin-off from Leiden University, based at the Leiden Bio Science Park. The company is dedicated to developing advanced exosome isolation technologies for biomarker discovery, diagnostics, and therapeutic applications. By leveraging its proprietary innovations, EXIT071 aims to accelerate the integration of exosome-based solutions into precision medicine.
EXIT071 has developed a platform technology, the EXIT (EXosome Isolation Tool), for scalable exosome isolation and biomarker analysis. Exosomes are nanosized extracellular vesicles present in body fluids, carrying molecular signatures of their originating cells, making them highly valuable for diagnostics and understanding disease mechanisms. EXIT071’s platform is based on its patented depletion zone isotachophoresis technology, invented at Leiden University, enabling simultaneous separation and enrichment of exosomes in a microfluidic chip. This technology seamlessly integrates with molecular analysis methods such as mass spectrometry, sequencing, PCR, enabling automated workflows for high-throughput biomarker analysis.
Read more about EXIT071 on their projectpage, or read their full press release below.
